The Experts below are selected from a list of 249 Experts worldwide ranked by ideXlab platform
Diane P. Calello - One of the best experts on this subject based on the ideXlab platform.
-
Naloxone Deserts in NJ Cities: Sociodemographic Factors Which May Impact Retail Pharmacy Naloxone Availability
Journal of Medical Toxicology, 2019Co-Authors: Kevin W Lozo, Christine Ramdin, Lewis S Nelson, Diane P. CalelloAbstract:IntroductionRetail pharmacies in NJ are permitted to dispense Naloxone without a prescription. However, not all pharmacies have participated in this effort, and it is not clear what factors may impact its availability. We sought to determine the Naloxone availability of select NJ cities and what sociodemographic factors are associated with its availability. We compared Naloxone availability in retail pharmacies to median household income, population, and the prevalence of opioid-related hospital visits (ORHV).MethodsAll retail pharmacies in ten New Jersey cities were surveyed by phone in February–July 2017. The standardized survey instrument asked scripted questions to each pharmacist concerning the stocking of Naloxone for dispensing. Median household income data and population data for each city were obtained from census.gov. Opioid-related hospital visits were obtained through the NJ SHAD database and the prevalence of ORHV was calculated. Naloxone availability was compared to median household income, population, and ORHV using Spearman’s rho and Pearson’s correlation.ResultsNaloxone availability in the 90 retail pharmacies we surveyed was 31% and ranged from 15.38 to 66.67% by city. An increase in median household income indicated more pharmacy Naloxone availability. An increase in population indicated less pharmacy Naloxone availability. While no significant relationship existed between ORHV and pharmacy Naloxone availability, we did identify individual cities with severe opioid-related public health concerns with limited Naloxone access.ConclusionsNaloxone deserts exist in select high-risk New Jersey cities, and pharmacy Naloxone availability may be positively related to median household income and negatively related to population.
-
Naloxone Deserts in NJ Cities: Sociodemographic Factors Which May Impact Retail Pharmacy Naloxone Availability.
Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2019Co-Authors: Kevin W Lozo, Christine Ramdin, Lewis S Nelson, Diane P. CalelloAbstract:Retail pharmacies in NJ are permitted to dispense Naloxone without a prescription. However, not all pharmacies have participated in this effort, and it is not clear what factors may impact its availability. We sought to determine the Naloxone availability of select NJ cities and what sociodemographic factors are associated with its availability. We compared Naloxone availability in retail pharmacies to median household income, population, and the prevalence of opioid-related hospital visits (ORHV). All retail pharmacies in ten New Jersey cities were surveyed by phone in February–July 2017. The standardized survey instrument asked scripted questions to each pharmacist concerning the stocking of Naloxone for dispensing. Median household income data and population data for each city were obtained from census.gov . Opioid-related hospital visits were obtained through the NJ SHAD database and the prevalence of ORHV was calculated. Naloxone availability was compared to median household income, population, and ORHV using Spearman’s rho and Pearson’s correlation. Naloxone availability in the 90 retail pharmacies we surveyed was 31% and ranged from 15.38 to 66.67% by city. An increase in median household income indicated more pharmacy Naloxone availability. An increase in population indicated less pharmacy Naloxone availability. While no significant relationship existed between ORHV and pharmacy Naloxone availability, we did identify individual cities with severe opioid-related public health concerns with limited Naloxone access. Naloxone deserts exist in select high-risk New Jersey cities, and pharmacy Naloxone availability may be positively related to median household income and negatively related to population.
Kevin W Lozo - One of the best experts on this subject based on the ideXlab platform.
-
Naloxone Deserts in NJ Cities: Sociodemographic Factors Which May Impact Retail Pharmacy Naloxone Availability
Journal of Medical Toxicology, 2019Co-Authors: Kevin W Lozo, Christine Ramdin, Lewis S Nelson, Diane P. CalelloAbstract:IntroductionRetail pharmacies in NJ are permitted to dispense Naloxone without a prescription. However, not all pharmacies have participated in this effort, and it is not clear what factors may impact its availability. We sought to determine the Naloxone availability of select NJ cities and what sociodemographic factors are associated with its availability. We compared Naloxone availability in retail pharmacies to median household income, population, and the prevalence of opioid-related hospital visits (ORHV).MethodsAll retail pharmacies in ten New Jersey cities were surveyed by phone in February–July 2017. The standardized survey instrument asked scripted questions to each pharmacist concerning the stocking of Naloxone for dispensing. Median household income data and population data for each city were obtained from census.gov. Opioid-related hospital visits were obtained through the NJ SHAD database and the prevalence of ORHV was calculated. Naloxone availability was compared to median household income, population, and ORHV using Spearman’s rho and Pearson’s correlation.ResultsNaloxone availability in the 90 retail pharmacies we surveyed was 31% and ranged from 15.38 to 66.67% by city. An increase in median household income indicated more pharmacy Naloxone availability. An increase in population indicated less pharmacy Naloxone availability. While no significant relationship existed between ORHV and pharmacy Naloxone availability, we did identify individual cities with severe opioid-related public health concerns with limited Naloxone access.ConclusionsNaloxone deserts exist in select high-risk New Jersey cities, and pharmacy Naloxone availability may be positively related to median household income and negatively related to population.
-
Naloxone Deserts in NJ Cities: Sociodemographic Factors Which May Impact Retail Pharmacy Naloxone Availability.
Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2019Co-Authors: Kevin W Lozo, Christine Ramdin, Lewis S Nelson, Diane P. CalelloAbstract:Retail pharmacies in NJ are permitted to dispense Naloxone without a prescription. However, not all pharmacies have participated in this effort, and it is not clear what factors may impact its availability. We sought to determine the Naloxone availability of select NJ cities and what sociodemographic factors are associated with its availability. We compared Naloxone availability in retail pharmacies to median household income, population, and the prevalence of opioid-related hospital visits (ORHV). All retail pharmacies in ten New Jersey cities were surveyed by phone in February–July 2017. The standardized survey instrument asked scripted questions to each pharmacist concerning the stocking of Naloxone for dispensing. Median household income data and population data for each city were obtained from census.gov . Opioid-related hospital visits were obtained through the NJ SHAD database and the prevalence of ORHV was calculated. Naloxone availability was compared to median household income, population, and ORHV using Spearman’s rho and Pearson’s correlation. Naloxone availability in the 90 retail pharmacies we surveyed was 31% and ranged from 15.38 to 66.67% by city. An increase in median household income indicated more pharmacy Naloxone availability. An increase in population indicated less pharmacy Naloxone availability. While no significant relationship existed between ORHV and pharmacy Naloxone availability, we did identify individual cities with severe opioid-related public health concerns with limited Naloxone access. Naloxone deserts exist in select high-risk New Jersey cities, and pharmacy Naloxone availability may be positively related to median household income and negatively related to population.
John Strang - One of the best experts on this subject based on the ideXlab platform.
-
are take home Naloxone programmes effective systematic review utilizing application of the bradford hill criteria
Addiction, 2016Co-Authors: Rebecca Mcdonald, John StrangAbstract:Fatal outcome of opioid overdose, once detected, is preventable through timely administration of the antidote Naloxone. Take-home Naloxone provision directly to opioid users for emergency use has been implemented recently in more than 15 countries worldwide, albeit mainly as pilot schemes and without formal evaluation. This systematic review assesses the effectiveness of take-home Naloxone, with two specific aims: (1) to study the impact of take-home Naloxone distribution on overdose-related mortality; and (2) to assess the safety of take-home Naloxone in terms of adverse events. Conclusions: Take-home Naloxone programmes are found to reduce overdose mortality among programme participants and in the community and have a low rate of adverse events.
-
clinical provision of improvised nasal Naloxone without experimental testing and without regulatory approval imaginative shortcut or dangerous bypass of essential safety procedures
Addiction, 2016Co-Authors: John Strang, Rebecca Mcdonald, Basak Tas, Ed DayAbstract:Context Take-home Naloxone is increasingly provided to prevent heroin overdose deaths. Naloxone 0.4-2.0 mg is licensed for use by injection. Some clinicians supply improvised nasal Naloxone kits (outside lisenced approval). Is this acceptable? Aims (1) To consider provision of improvised nasal Naloxone in clinical practice and (2) to search for evidence for pharmacokinetics and effectiveness (versus injection). Methods (1) To document existing nasal Naloxone schemes and published evidence of pharmacokinetics (systematic search of the CINAHL, Cochrane, EMBASE and MEDLINE databases and 18 records included in narrative synthesis). (2) To analyse ongoing studies investigating nasal Naloxone (WHO International Clinical Trials Registry Platform and US NIH RePORT databases). Findings (1) Multiple studies report overdose reversals following administration of improvised intranasal Naloxone. (2) Overdose reversal after nasal Naloxone is frequent but may not always occur. (3) Until late 2015, the only commercially available Naloxone concentrations were 0.4 mg/ml and 2 mg/2 ml. Nasal medications are typically 0.05-0.25 ml of fluid per nostril. The only published study of pharmacokinetics and bioavailability finds that nasal Naloxone has poor bioavailability. Questions for debate (1) Why are pharmacokinetics and bioavailability data for nasal Naloxone not available before incorporation into standard clinical practice? (2) Does nasal Naloxone have the potential to become a reliable clinical formulation? (3) What pre-clinical and clinical studies should precede utilization of novel Naloxone formulations as standard emergency medications? Conclusions The addictions treatment field has rushed prematurely into the use of improvised nasal Naloxone kits. Evidence of adequate bioavailability and acceptable pharmacokinetic curves are vital preliminary steps, especially when effective approved formulations exist. Language: en
-
Naloxone without the needle - systematic review of candidate routes for non-injectable Naloxone for opioid overdose reversal
Drug and Alcohol Dependence, 2016Co-Authors: John Strang, Rebecca Mcdonald, Abdulmalik Alqurshi, Paul G Royall, David Taylor, Ben ForbesAbstract:Abstract Introduction Deaths from opioid overdose can be prevented through administration of the antagonist Naloxone, which has been licensed for injection since the 1970s. To support wider availability of Naloxone in community settings, novel non-injectable Naloxone formulations are being developed, suitable for emergency use by non-medical personnel. Objectives 1) Identify candidate routes of injection-free Naloxone administration potentially suitable for emergency overdose reversal; 2) consider pathways for developing and evaluating novel Naloxone formulations. Methods A three-stage analysis of candidate routes of administration was conducted: 1) assessment of all 112 routes of administration identified by FDA against exclusion criteria. 2) Scrutiny of empirical data for identified candidate routes, searching PubMed and WHO International Clinical Trials Registry Platform using search terms “Naloxone AND [route of administration]”. 3) Examination of routes for feasibility and against the inclusion criteria. Results Only three routes of administration met inclusion criteria: nasal, sublingual and buccal. Products are currently in development and being studied. Pharmacokinetic data exist only for nasal Naloxone, for which product development is more advanced, and one concentrated nasal spray was granted licence in the US in 2015. However, buccal Naloxone may also be viable and may have different characteristics. Conclusion After 40 years of injection-based Naloxone treatment, non-injectable routes are finally being developed. Nasal Naloxone has recently been approved and will soon be field-tested, buccal Naloxone holds promise, and it is unclear what sublingual Naloxone will contribute. Development and approval of reliable non-injectable formulations will facilitate wider Naloxone provision across the community internationally.
-
heroin overdose resuscitation with Naloxone patient uses own prescribed supply to save the life of a peer
Case Reports, 2015Co-Authors: Ian Winston, Rebecca Mcdonald, Basak Tas, John StrangAbstract:Opiate overdose is the primary cause of death among injection-drug users, representing a major public health concern worldwide. Opiate overdose can be reversed through timely administration of Naloxone, and users have expressed willingness to carry the antidote for emergency use (take-home Naloxone). In November 2014, new WHO guidelines identified that Naloxone should be made available to anyone at risk of witnessing an overdose. We present the case of a 46-year-old man in opioid-maintenance treatment who used take-home Naloxone to rescue an overdose victim. This is the first- ever account of a patient using dose titration of Naloxone to restore respiratory function while minimising the risk of adverse effects. To improve the safety of take-home Naloxone, the authors call for clinicians involved in the treatment of opiate users to: prescribe take-home Naloxone to all patients; forewarn patients of potential side effects; and instruct patients in Naloxone dose titration.
Christine Ramdin - One of the best experts on this subject based on the ideXlab platform.
-
Naloxone Deserts in NJ Cities: Sociodemographic Factors Which May Impact Retail Pharmacy Naloxone Availability
Journal of Medical Toxicology, 2019Co-Authors: Kevin W Lozo, Christine Ramdin, Lewis S Nelson, Diane P. CalelloAbstract:IntroductionRetail pharmacies in NJ are permitted to dispense Naloxone without a prescription. However, not all pharmacies have participated in this effort, and it is not clear what factors may impact its availability. We sought to determine the Naloxone availability of select NJ cities and what sociodemographic factors are associated with its availability. We compared Naloxone availability in retail pharmacies to median household income, population, and the prevalence of opioid-related hospital visits (ORHV).MethodsAll retail pharmacies in ten New Jersey cities were surveyed by phone in February–July 2017. The standardized survey instrument asked scripted questions to each pharmacist concerning the stocking of Naloxone for dispensing. Median household income data and population data for each city were obtained from census.gov. Opioid-related hospital visits were obtained through the NJ SHAD database and the prevalence of ORHV was calculated. Naloxone availability was compared to median household income, population, and ORHV using Spearman’s rho and Pearson’s correlation.ResultsNaloxone availability in the 90 retail pharmacies we surveyed was 31% and ranged from 15.38 to 66.67% by city. An increase in median household income indicated more pharmacy Naloxone availability. An increase in population indicated less pharmacy Naloxone availability. While no significant relationship existed between ORHV and pharmacy Naloxone availability, we did identify individual cities with severe opioid-related public health concerns with limited Naloxone access.ConclusionsNaloxone deserts exist in select high-risk New Jersey cities, and pharmacy Naloxone availability may be positively related to median household income and negatively related to population.
-
Naloxone Deserts in NJ Cities: Sociodemographic Factors Which May Impact Retail Pharmacy Naloxone Availability.
Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2019Co-Authors: Kevin W Lozo, Christine Ramdin, Lewis S Nelson, Diane P. CalelloAbstract:Retail pharmacies in NJ are permitted to dispense Naloxone without a prescription. However, not all pharmacies have participated in this effort, and it is not clear what factors may impact its availability. We sought to determine the Naloxone availability of select NJ cities and what sociodemographic factors are associated with its availability. We compared Naloxone availability in retail pharmacies to median household income, population, and the prevalence of opioid-related hospital visits (ORHV). All retail pharmacies in ten New Jersey cities were surveyed by phone in February–July 2017. The standardized survey instrument asked scripted questions to each pharmacist concerning the stocking of Naloxone for dispensing. Median household income data and population data for each city were obtained from census.gov . Opioid-related hospital visits were obtained through the NJ SHAD database and the prevalence of ORHV was calculated. Naloxone availability was compared to median household income, population, and ORHV using Spearman’s rho and Pearson’s correlation. Naloxone availability in the 90 retail pharmacies we surveyed was 31% and ranged from 15.38 to 66.67% by city. An increase in median household income indicated more pharmacy Naloxone availability. An increase in population indicated less pharmacy Naloxone availability. While no significant relationship existed between ORHV and pharmacy Naloxone availability, we did identify individual cities with severe opioid-related public health concerns with limited Naloxone access. Naloxone deserts exist in select high-risk New Jersey cities, and pharmacy Naloxone availability may be positively related to median household income and negatively related to population.
Lewis S Nelson - One of the best experts on this subject based on the ideXlab platform.
-
Naloxone Deserts in NJ Cities: Sociodemographic Factors Which May Impact Retail Pharmacy Naloxone Availability
Journal of Medical Toxicology, 2019Co-Authors: Kevin W Lozo, Christine Ramdin, Lewis S Nelson, Diane P. CalelloAbstract:IntroductionRetail pharmacies in NJ are permitted to dispense Naloxone without a prescription. However, not all pharmacies have participated in this effort, and it is not clear what factors may impact its availability. We sought to determine the Naloxone availability of select NJ cities and what sociodemographic factors are associated with its availability. We compared Naloxone availability in retail pharmacies to median household income, population, and the prevalence of opioid-related hospital visits (ORHV).MethodsAll retail pharmacies in ten New Jersey cities were surveyed by phone in February–July 2017. The standardized survey instrument asked scripted questions to each pharmacist concerning the stocking of Naloxone for dispensing. Median household income data and population data for each city were obtained from census.gov. Opioid-related hospital visits were obtained through the NJ SHAD database and the prevalence of ORHV was calculated. Naloxone availability was compared to median household income, population, and ORHV using Spearman’s rho and Pearson’s correlation.ResultsNaloxone availability in the 90 retail pharmacies we surveyed was 31% and ranged from 15.38 to 66.67% by city. An increase in median household income indicated more pharmacy Naloxone availability. An increase in population indicated less pharmacy Naloxone availability. While no significant relationship existed between ORHV and pharmacy Naloxone availability, we did identify individual cities with severe opioid-related public health concerns with limited Naloxone access.ConclusionsNaloxone deserts exist in select high-risk New Jersey cities, and pharmacy Naloxone availability may be positively related to median household income and negatively related to population.
-
Naloxone Deserts in NJ Cities: Sociodemographic Factors Which May Impact Retail Pharmacy Naloxone Availability.
Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2019Co-Authors: Kevin W Lozo, Christine Ramdin, Lewis S Nelson, Diane P. CalelloAbstract:Retail pharmacies in NJ are permitted to dispense Naloxone without a prescription. However, not all pharmacies have participated in this effort, and it is not clear what factors may impact its availability. We sought to determine the Naloxone availability of select NJ cities and what sociodemographic factors are associated with its availability. We compared Naloxone availability in retail pharmacies to median household income, population, and the prevalence of opioid-related hospital visits (ORHV). All retail pharmacies in ten New Jersey cities were surveyed by phone in February–July 2017. The standardized survey instrument asked scripted questions to each pharmacist concerning the stocking of Naloxone for dispensing. Median household income data and population data for each city were obtained from census.gov . Opioid-related hospital visits were obtained through the NJ SHAD database and the prevalence of ORHV was calculated. Naloxone availability was compared to median household income, population, and ORHV using Spearman’s rho and Pearson’s correlation. Naloxone availability in the 90 retail pharmacies we surveyed was 31% and ranged from 15.38 to 66.67% by city. An increase in median household income indicated more pharmacy Naloxone availability. An increase in population indicated less pharmacy Naloxone availability. While no significant relationship existed between ORHV and pharmacy Naloxone availability, we did identify individual cities with severe opioid-related public health concerns with limited Naloxone access. Naloxone deserts exist in select high-risk New Jersey cities, and pharmacy Naloxone availability may be positively related to median household income and negatively related to population.
